StockNoteStockNote
VIDIPHA Central Pharmaceutical Joint Stock Company (VDP) was established in 2003 on the basis of equitization of the Central Pharmaceutical Industry Development Company. The company operates mainly in the field of manufacturing, trading, importing and exporting pharmaceuticals and medicinal materials. Vidipha isone of the first pharmaceutical companies in Vietnamto meet GMP-ASEAN standards. In recent years, the Company has invested in building a modern factory meeting GMP-WHO standards in Binh Duong province with 10 drug production lines. With a total area of 2100 m2, the head office of the Company is the place where the office and the warehouse of finished products are located. VDP currently produces more than 300 drug items, divided into 04 main groups, including tablets, water pills, powders and ointments. The company has built a centralized distribution system mainly in Ho Chi Minh City and Hanoi. On August 15, 2017, VDP officially traded on the Ho Chi Minh City Stock Exchange (hose).
VDP currently has a market capitalization of roughly VND 960 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 14,5x is 26% above its own 8-year average (11,6x), suggesting the stock is trading richer than its historical norm. P/B stands at 1,2x, 8% above its multi-year average of 1,1x. Return on equity (ROE) is at 8,6%. Its debt-to-equity ratio of 0,2x is low, reflecting a conservative capital structure. In 2025, revenue grew 5% year-on-year while after-tax profit fell 11%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.